var title_f38_60_39872="Emergency department sedation of ventilated adults";
var content_f38_60_39872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Emergency department sedation of ventilated adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 620px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm is a general guideline for the use of analgesics and sedatives. Refer to the text for clinical and pharmacologic issues that dictate optimal drug selection, recommended assessment scales, and precautions for patient monitoring. Doses are approximate for a 70-kg adult.",
"    <div class=\"footnotes\">",
"     IVP: intravenous push.",
"     <br>",
"      * Numeric rating scale or other pain scale.",
"      <br>",
"       &bull; Riker Sedation-Agitation Scale or other sedation scale.",
"       <br>",
"        &Delta; Confusion Assessment Method for the ICU.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jacobi, J, Fraser, GL, Coursin, DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119. Official Journal of the Society of Critical Care Medicine, Copyright &copy; 2002 Society of Critical Care Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39872=[""].join("\n");
var outline_f38_60_39872=null;
var title_f38_60_39873="Aromatic ammonia spirit: Drug information";
var content_f38_60_39873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aromatic ammonia spirit: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Respiratory Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Fainting:",
"     </b>",
"     Inhalation: Slowly inhale the vapors of one crushed ampul or opened bottle of solution until fainting resolves.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13259561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, for inhalation: 1.7% to 2.1% (0.33 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The vapor of aromatic ammonia spirit may be inhaled; keep away from eyes and skin. Crush one ampul between fingers or open container of solution; slowly inhale when ampule or solution is held ~4 inches away from nostrils.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention or treatment of fainting",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea, cough, irritation to nasal mucosa",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ammonia or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13259549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fainting: Patients should be evaluated for the cause of fainting, especially when accompanied by flushed face.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular disease: Use with caution in patients with diseases of the eye; conditions may worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma, bronchitis, emphysema, or other chronic lung conditions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8622 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39873=[""].join("\n");
var outline_f38_60_39873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134186\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134180\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13259561\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134181\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134173\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134163\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134175\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134174\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134184\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134177\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13259549\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298739\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134169\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8622|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39874="CXR MRI scimitar syndrome";
var content_f38_60_39874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    CXR MRI scimitar syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chestradiography of a patient with scimitar syndrome showing a rightside anomalous pulmonary vein (Panel A), which was confirmed by magnetic resonance imaging (Panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George Taylor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39874=[""].join("\n");
var outline_f38_60_39874=null;
var title_f38_60_39875="Lactic acid with ammonium hydroxide: Patient drug information";
var content_f38_60_39875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lactic acid with ammonium hydroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19059?source=see_link\">",
"     see \"Lactic acid with ammonium hydroxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29939?source=see_link\">",
"     see \"Lactic acid with ammonium hydroxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AmLactin&reg; [OTC];",
"     </li>",
"     <li>",
"      Geri-Hydrolac&trade; [OTC];",
"     </li>",
"     <li>",
"      Geri-Hydrolac&trade;-12 [OTC];",
"     </li>",
"     <li>",
"      Lac-Hydrin&reg;;",
"     </li>",
"     <li>",
"      Lac-Hydrin&reg; Five [OTC];",
"     </li>",
"     <li>",
"      LAClotion&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702352",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lactic acid, ammonium hydroxide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11773 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39875=[""].join("\n");
var outline_f38_60_39875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013722\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013721\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013726\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013727\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013729\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013724\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013725\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013730\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013731\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19059?source=related_link\">",
"      Lactic acid with ammonium hydroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/15/29939?source=related_link\">",
"      Lactic acid with ammonium hydroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39876="Protriptyline: Patient drug information";
var content_f38_60_39876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Protriptyline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/5/10327?source=see_link\">",
"     see \"Protriptyline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44550?source=see_link\">",
"     see \"Protriptyline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vivactil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to protriptyline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11007 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39876=[""].join("\n");
var outline_f38_60_39876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017986\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017988\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017987\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017992\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017993\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017995\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017990\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017991\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017996\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017997\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/5/10327?source=related_link\">",
"      Protriptyline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44550?source=related_link\">",
"      Protriptyline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39877="Hyoscyamine: Patient drug information";
var content_f38_60_39877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hyoscyamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=see_link\">",
"     see \"Hyoscyamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/7/26741?source=see_link\">",
"     see \"Hyoscyamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anaspaz&reg;;",
"     </li>",
"     <li>",
"      ED-SPAZ;",
"     </li>",
"     <li>",
"      HyoMax&reg; -SR;",
"     </li>",
"     <li>",
"      HyoMax&reg;-SL;",
"     </li>",
"     <li>",
"      HyoMax&trade;-DT;",
"     </li>",
"     <li>",
"      HyoMax&trade;-FT;",
"     </li>",
"     <li>",
"      Hyosyne;",
"     </li>",
"     <li>",
"      Levbid&reg;;",
"     </li>",
"     <li>",
"      Levsin&reg;;",
"     </li>",
"     <li>",
"      Levsin&reg;/SL;",
"     </li>",
"     <li>",
"      NuLev&reg;;",
"     </li>",
"     <li>",
"      Oscimin;",
"     </li>",
"     <li>",
"      Symax&reg; DuoTab;",
"     </li>",
"     <li>",
"      Symax&reg; FasTab;",
"     </li>",
"     <li>",
"      Symax&reg; SL;",
"     </li>",
"     <li>",
"      Symax&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levsin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help motion sickness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the speed in the stomach and GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat GI (gastrointestinal) ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat irritable bowel syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat muscle spasms of the GI (gastrointestinal) tract, gallbladder system, or urinary system.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hyoscyamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3770778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, enlarged colon, glaucoma, myasthenia gravis, slow-moving GI (gastrointestinal) tract, ulcerative colitis, or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for irritable bowel syndrome or spasms of the GI (gastrointestinal) tract, take 30 to 60 minutes before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir, solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on the tongue and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2876785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2893560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         <b>",
"          Under the tongue (sublingual) tablet:",
"         </b>",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3370402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place under tongue and let melt all the way. Do not chew, suck or swallow tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10749 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39877=[""].join("\n");
var outline_f38_60_39877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181213\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023223\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023222\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023227\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023228\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023230\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023225\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023226\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023231\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023232\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=related_link\">",
"      Hyoscyamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/7/26741?source=related_link\">",
"      Hyoscyamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39878="Portion-size estimator";
var content_f38_60_39878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Portion-size estimator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 697px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39878=[""].join("\n");
var outline_f38_60_39878=null;
var title_f38_60_39879="Primary dysmenorrhea in adult women: Clinical features and diagnosis";
var content_f38_60_39879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary dysmenorrhea in adult women: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Roger P Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Andrew M Kaunitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39879/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/60/39879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysmenorrhea, or painful menstruation, is a common problem experienced by women in their reproductive years. When severe, it interferes with the performance of daily activities, often leading to absenteeism from school, work, and other responsibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21086905\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF PRIMARY AND SECONDARY DYSMENORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For clinical purposes, dysmenorrhea is divided into two broad categories, primary and secondary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary dysmenorrhea refers to the presence of recurrent, crampy, lower abdominal pain that occurs during menses in the absence of demonstrable disease that could account for these symptoms.",
"     </li>",
"     <li>",
"      Secondary dysmenorrhea has the same clinical features, but occurs in women with a disorder that could account for their symptoms, such as endometriosis, adenomyosis, or uterine fibroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181096\">",
"    <span class=\"h1\">",
"     PRIMARY DYSMENORRHEA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In surveys, 50 to 90 percent of reproductive-aged women worldwide describe experiencing painful menstrual periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. The majority of these women are young and have primary dysmenorrhea. The prevalence of primary dysmenorrhea decreases with advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of women with primary dysmenorrhea do not have any risk factors for the disorder. In a systematic review that evaluated risk factors for dysmenorrhea, multiple demographic, environmental, gynecological, and psychological factors appeared to be associated with the disorder, including age &lt;30 years, body mass index &lt;20",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    smoking, menarche before age 12, longer menstrual",
"    <span class=\"nowrap\">",
"     cycles/duration",
"    </span>",
"    of bleeding, irregular or heavy menstrual flow, and history of sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/12\">",
"     12",
"    </a>",
"    ]. Younger age at first childbirth and higher parity were associated with a reduced risk. There appears to be a familial predisposition to primary dysmenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins released from endometrial sloughing at the beginning of menses play a major role in inducing contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/14\">",
"     14",
"    </a>",
"    ]. These contractions are nonrhythmic or incoordinate, occur at high frequency (more than 4 or 5 per 10 minutes), often begin from an elevated basal tone (more than 10 mmHg), and result in high intrauterine pressures (frequently more than 150 to 180 mmHg, sometimes exceeding 400 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/15\">",
"     15",
"    </a>",
"    ]. When uterine pressure exceeds arterial pressure, uterine ischemia develops and anaerobic metabolites accumulate, which stimulate type C pain neurons resulting in dysmenorrhea.",
"   </p>",
"   <p>",
"    This hypothesis is supported by multiple lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial concentrations of prostaglandin E2 and prostaglandin F2 alpha are elevated in primary dysmenorrhea and correlate with the severity of pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exogenous administration of prostaglandins reproduce the symptoms (uterine contractions, nausea, vomiting, diarrhea, headache, backache) associated with primary dysmenorrhea.",
"     </li>",
"     <li>",
"      Doppler studies show that women with primary dysmenorrhea have elevated uterine artery Doppler indices (ie, higher resistance to blood flow in the uterine arteries) during menses compared to women without dysmenorrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with primary dysmenorrhea treated with nonsteroidal anti-inflammatory drugs (NSAIDs) note an improvement in symptoms over time in parallel with the decrease in intrauterine",
"      <span class=\"nowrap\">",
"       pressure/contractility",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef59146 \" href=\"mobipreview.htm?3/11/3262\">",
"       figure 1",
"      </a>",
"      ) and menstrual fluid prostaglandin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/16,19\">",
"       16,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21088032\">",
"    <span class=\"h3\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dysmenorrhea typically begins during adolescence, after ovulatory cycles first become established. Maturation of the hypothalamic-pituitary-gonadal axis leading to ovulation occurs at different rates; approximately 18 to 45 percent of adolescents have ovulatory cycles two years postmenarche, 45 to 70 percent by two to four years, and 80 percent by four to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain starts one to two days before or with the onset of menstrual bleeding and then gradually diminishes over 12 to 72 hours. It is recurrent, occurring in most, if not all, menstrual cycles. The pain is usually crampy and intermittently intense, but may be a continuous dull ache. It is usually confined to the lower abdomen and suprapubic area. Although the pain is usually strongest in the midline, some women also have severe back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thigh pain. Nonmidline pain, especially if unilateral, suggests a uterine anomaly or alternative diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of the pain ranges from mild to severe (",
"    <a class=\"graphic graphic_table graphicRef65347 \" href=\"mobipreview.htm?22/16/22795\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/6\">",
"     6",
"    </a>",
"    ]. When Canadian researchers interviewed a random sample of 934 women &ge;18 years old with primary dysmenorrhea, 60 percent described their pain as moderate or severe, 50 percent reported limiting their activity, and 17 percent reported missing school or work because of dysmenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea, diarrhea, fatigue, headache, and a general sense of malaise often accompany the pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21088281\">",
"    <span class=\"h3\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no physical findings associated with primary dysmenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21088288\">",
"    <span class=\"h3\">",
"     Laboratory and imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dysmenorrhea is not associated with any laboratory abnormalities or abnormal findings on imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52182240\">",
"    <span class=\"h3\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dysmenorrhea tends to improve with advancing age and often improves after childbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary dysmenorrhea is made clinically in women with recurrent, crampy, midline, pelvic pain that starts just before or with the onset of menstrual bleeding and then gradually diminishes over 12 to 72 hours",
"    <strong>",
"     and",
"    </strong>",
"    who have no evidence of other disorders that could account for the pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181508\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the diagnostic evaluation are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclude the presence of other disorders, such as pelvic inflammatory disease, that could account for the patient&rsquo;s symptoms and would change the diagnosis to secondary dysmenorrhea. Disorders that have been associated with secondary dysmenorrhea are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef78903 \" href=\"mobipreview.htm?18/0/18443\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Evaluate disease severity: how does dysmenorrhea impact the patient&rsquo;s daily activities, such as attendance at school, work, or exercise? Grading dysmenorrhea according to the severity of pain and limitation of daily activities may help guide treatment decisions (",
"      <a class=\"graphic graphic_table graphicRef65347 \" href=\"mobipreview.htm?22/16/22795\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link\">",
"       \"Treatment of primary dysmenorrhea in adult women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obtain information about previous medications (dose and duration of therapy) and their efficacy in relieving the patient&rsquo;s symptoms. Resolution or significant amelioration of symptoms with nonsteroidal anti-inflammatory drugs (NSAIDs) or hormonal contraception supports the diagnosis of primary dysmenorrhea and also helps in planning further therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181654\">",
"    <span class=\"h3\">",
"     Exclusion of secondary dysmenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation should, in general, include a detailed history and physical examination to look for signs and symptoms suggestive of pelvic pathologies, such as pelvic inflammatory disease, endometriosis, adenomyosis, or fibroids. Laboratory tests, imaging studies, and laparoscopy are not required to exclude these disorders, but should be performed, as indicated, if pelvic disease is strongly suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181574\">",
"    <span class=\"h4\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings suggest the presence of pelvic pathology, consistent with secondary dysmenorrhea:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset of dysmenorrhea after age 25. However, endometriosis may occur in adolescents (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11402?source=see_link\">",
"       \"Diagnosis and treatment of endometriosis in adolescents\"",
"      </a>",
"      ) and a congenital uterine outlet obstruction can cause dysmenorrhea shortly after menarche",
"     </li>",
"     <li>",
"      Abnormal uterine bleeding (eg, menorrhagia, oligomenorrhea, intermenstrual bleeding)",
"     </li>",
"     <li>",
"      Nonmidline pelvic pain",
"     </li>",
"     <li>",
"      Absence of nausea, vomiting, diarrhea, back pain, dizziness, or headache during menstruation",
"     </li>",
"     <li>",
"      Presence of dyspareunia or dyschezia",
"     </li>",
"     <li>",
"      Progression in symptom severity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pelvic inflammatory disease is most common in women 15 to 25 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It is characterized by lower abdominal pain, which is usually bilateral and ranges from mild to severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/26\">",
"     26",
"    </a>",
"    ]. The onset of pain is often during or shortly after menses, and may worsen during coitus or with jarring movement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/27\">",
"     27",
"    </a>",
"    ]. Abnormal uterine bleeding occurs in one-third or more of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/28\">",
"     28",
"    </a>",
"    ]. New vaginal discharge, urethritis, proctitis, fever, and chills can be associated signs but are neither sensitive nor specific for the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 5 percent of reproductive age women have endometriosis and it is one of the most common gynecological causes of secondary dysmenorrhea. Women with endometriosis typically report pelvic pain that is both related to menses and occurs at times other than menses. They may have premenstrual spotting, dyspareunia, dyschezia, poor relief of symptoms with NSAIDs, progressively worsening symptoms, and inability to attend work or school during menses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with adenomyosis typically present with dysmenorrhea after age 35 years, while women with primary dysmenorrhea typically develop symptoms before 25 years of age. The pain associated with adenomyosis is often limited to menses, but noncyclic chronic pelvic pain also occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibroids are rare in adolescents, but become common by age 35 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/29\">",
"     29",
"    </a>",
"    ]. Dyspareunia and noncyclic pelvic pain are more common manifestations of fibroid-related pain than dysmenorrhea, which is usually mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/30\">",
"     30",
"    </a>",
"    ]. In women with symptomatic uterine fibroids, worsening dysmenorrhea is characteristically accompanied by increasing menstrual flow (menorrhagia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some uterine abnormalities, such as a noncommunicating accessory uterine cavity with functioning endometrium or juvenile cystic adenomyosis, present with severe dysmenorrhea soon after menarche and typically by age 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Pain may also occur pre- and post- menses. Physical examination may detect a tender mass on the uterus. Imaging studies are useful for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181817\">",
"    <span class=\"h4\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with primary dysmenorrhea have a normal pelvic examination. Women with secondary dysmenorrhea may also have a normal examination, although physical findings often occur and can be perceived on pelvic examination. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Findings in pelvic inflammatory disease include: (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Purulent endocervical discharge",
"     </li>",
"     <li>",
"      Acute cervical motion and adnexal tenderness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 percent of women with secondary dysmenorrhea due to endometriosis have physical findings on pelvic examination that suggest the presence of pelvic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]: (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Uterosacral ligament abnormalities, such as nodularity, thickening, or focal tenderness",
"     </li>",
"     <li>",
"      Lateral displacement of the cervix due to asymmetric involvement of one uterosacral ligament by endometriosis, causing it to shorten (",
"      <a class=\"graphic graphic_figure graphicRef59765 \" href=\"mobipreview.htm?10/47/10997\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical stenosis",
"     </li>",
"     <li>",
"      Adnexal enlargement from an endometrioma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenomyosis may be associated with a bulky, globular, mildly tender uterus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=see_link\">",
"       \"Uterine adenomyosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibroids typically result in an enlarged, irregularly-shaped, nontender uterus, which may also be palpable abdominally. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H5287492#H5287492\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Pelvic examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cervical or vaginal anomalies increase the likelihood of a congenital obstructed uterine abnormality, such as a rudimentary uterine horn. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link\">",
"       \"Congenital cervical anomalies and benign cervical lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vulvar varices may occur in pelvic congestion syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30681?source=see_link\">",
"       \"Vulvovaginal varicosities and pelvic congestion syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872903\">",
"    <span class=\"h4\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating potential causes of dysmenorrhea, laboratory testing is only useful for diagnosis of pelvic inflammatory disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical practice guidelines in the United States recommend routine chlamydia screening for sexually-active women below the age of 25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39879/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Testing for gonorrhea is probably not necessary if the patient's only symptom is primary dysmenorrhea, but may be considered in populations where the prevalence of gonorrhea is high. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181831\">",
"    <span class=\"h4\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination is most appropriate for patients in whom an underlying anatomic abnormality is suspected by history or physical examination and cannot be confirmed by other clinical means. Pelvic ultrasonography can also be useful in obese women when findings on bimanual examination are unclear. In adolescents with primary dysmenorrhea, performing transabdominal pelvic sonography instead of a bimanual examination to exclude pelvic pathology is appropriate if the clinical history is atypical or initial treatment does not reduce symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/25/31125?source=see_link\">",
"     \"Primary dysmenorrhea in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic ultrasonography is highly sensitive for detecting adnexal masses (eg, abscess, ovarian neoplasia, hydrosalpinges), fibroids, and uterine anomalies, but only moderately sensitive for diagnosis of adenomyosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic ultrasound may identify small pelvic masses (less than 4 cm in diameter) consistent with endometriosis or thickened fallopian tubes and not detected by bimanual examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Imaging techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873202\">",
"    <span class=\"h4\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic laparoscopy is rarely required because the cause of dysmenorrhea can almost always be determined by history and physical examination, supplemented by imaging studies when needed. Laparoscopy has a role in diagnosis and treatment of endometriosis, but the timing of laparoscopy depends on several factors including the age of the woman, symptom response to empiric therapy, and fertility issues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11402?source=see_link\">",
"     \"Diagnosis and treatment of endometriosis in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the treatment of endometriosis\", section on 'Indications for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52181351\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of crampy pelvic pain and uterine bleeding is also characteristic of miscarriage and ectopic pregnancy. These disorders should be suspected in a woman with new onset of pain and recent menstrual irregularity, and are readily excluded by a negative pregnancy test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many causes of acute and chronic pelvic pain either not associated with or incidental to menses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=see_link\">",
"     \"Evaluation of acute pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/25/11666?source=see_link\">",
"       \"Patient information: Painful periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/47/755?source=see_link\">",
"       \"Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary dysmenorrhea is characterized by recurrent, crampy, midline lower abdominal pain that occurs during menses in the absence of demonstrable disease that could account for the pain. Secondary dysmenorrhea is the occurrence of painful menses in the presence of a disease that could account for the pain (",
"      <a class=\"graphic graphic_table graphicRef78903 \" href=\"mobipreview.htm?18/0/18443\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21086905\">",
"       'Definitions of primary and secondary dysmenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary dysmenorrhea is caused by intense uterine contractions that result in uterine ischemia. Prostaglandins release from the endometrium at the beginning of menses and are a major cause of these contractions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain begins with the onset of menses and gradually diminishes over 12 to 72 hours. Additional symptoms that may be present include nausea, diarrhea, fatigue, headache, and a general sense of malaise. (See",
"      <a class=\"local\" href=\"#H21088032\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of primary dysmenorrhea is based upon the presence of characteristic clinical features in the absence of demonstrable disease that could account for the pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary dysmenorrhea is excluded primarily by history and physical examination. The most common causes of secondary dysmenorrhea are pelvic inflammatory disease and endometriosis. Laboratory tests and imaging studies are not mandatory to exclude disorders associated with secondary dysmenorrhea, but should be performed, as indicated, if pelvic disease is suspected. (See",
"      <a class=\"local\" href=\"#H52181654\">",
"       'Exclusion of secondary dysmenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of crampy pelvic pain and uterine bleeding is also characteristic of miscarriage and ectopic pregnancy. These disorders should be suspected in a woman with new onset of pelvic pain and recent menstrual irregularity, and are readily excluded by a negative pregnancy test. (See",
"      <a class=\"local\" href=\"#H52181351\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/1\">",
"      Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/2\">",
"      Wilson CA, Keye WR Jr. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adolesc Health Care 1989; 10:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/3\">",
"      Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/4\">",
"      Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/5\">",
"      Burnett MA, Antao V, Black A, et al. Prevalence of primary dysmenorrhea in Canada. J Obstet Gynaecol Can 2005; 27:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/6\">",
"      Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982; 144:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/7\">",
"      Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol 2010; 152:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/8\">",
"      Ortiz MI, Rangel-Flores E, Carrillo-Alarc&oacute;n LC, Veras-Godoy HA. Prevalence and impact of primary dysmenorrhea among Mexican high school students. Int J Gynaecol Obstet 2009; 107:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/9\">",
"      Polat A, Celik H, Gurates B, et al. Prevalence of primary dysmenorrhea in young adult female university students. Arch Gynecol Obstet 2009; 279:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/10\">",
"      Hillen TI, Grbavac SL, Johnston PJ, et al. Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment. J Adolesc Health 1999; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/11\">",
"      Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990; 97:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/12\">",
"      Latthe P, Mignini L, Gray R, et al. Factors predisposing women to chronic pelvic pain: systematic review. BMJ 2006; 332:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/13\">",
"      Widholm O, Kantero RL. A statistical analysis of the menstrual patterns of 8,000 Finnish girls and their mothers. Acta Obstet Gynecol Scand Suppl 1971; 14:Suppl 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/14\">",
"      Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. Am J Obstet Gynecol 1978; 130:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/15\">",
"      Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/16\">",
"      Chan WY, Dawood MY, Fuchs F. Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid. Am J Obstet Gynecol 1979; 135:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/17\">",
"      Altunyurt S, G&ouml;l M, Altunyurt S, et al. Primary dysmenorrhea and uterine blood flow: a color Doppler study. J Reprod Med 2005; 50:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/18\">",
"      Dmitrovi�� R. Transvaginal color Doppler study of uterine blood flow in primary dysmenorrhea. Acta Obstet Gynecol Scand 2000; 79:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/19\">",
"      Smith RP. The dynamics of nonsteroidal anti-inflammatory therapy for primary dysmenorrhea. Obstet Gynecol 1987; 70:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/20\">",
"      Hertweck SP. Dysfunctional uterine bleeding. Obstet Gynecol Clin North Am 1992; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/21\">",
"      Borah T, Das A, Panda S, Singh S. A case of unilateral dysmenorrhea. J Hum Reprod Sci 2010; 3:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/22\">",
"      Prouty M. Headache and stomach ache: significant symptoms of ulcer in childhood. Review of 216 cases of peptic ulcer. Wis Med J 1966; 65:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/23\">",
"      Chan WY, Dawood MY. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res 1980; 8:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/24\">",
"      Forslin L, Falk V, Danielsson D. Changes in the incidence of acute gonococcal and nongonococcal salpingitis. A five-year study from an urban area of central Sweden. Br J Vener Dis 1978; 54:247.",
"     </a>",
"    </li>",
"    <li>",
"     Westrom, L, Mardh PA. Epidemiology, etiology, and prognosis of acute salpingitis: A study of 1,457 laparoscopically verified cases. In: Nongonococcal Urethritis and Related Diseases, Hobson D, Holmes KK (Eds), Am Soc Microbiol, Washington DC 1977. p.84.",
"    </li>",
"    <li>",
"     Westrom L, Mardh PA. Epidemiology, etiology, and prognosis of acute salpingitis: A study of 1,457 laparoscopically verified cases. In: Nongonococcal Urethritis and Related Diseases, Hobson D, Holmes KK (Eds), Am Soc Microbiol, Washington, DC 1977. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/27\">",
"      Korn AP, Hessol NA, Padian NS, et al. Risk factors for plasma cell endometritis among women with cervical Neisseria gonorrhoeae, cervical Chlamydia trachomatis, or bacterial vaginosis. Am J Obstet Gynecol 1998; 178:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/28\">",
"      Jacobson L, Westr&ouml;m L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostic value of routine laparoscopy. Am J Obstet Gynecol 1969; 105:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/29\">",
"      Wright KN, Laufer MR. Leiomyomas in adolescents. Fertil Steril 2011; 95:2434.e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/30\">",
"      Lippman SA, Warner M, Samuels S, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003; 80:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/31\">",
"      Dogan E, Gode F, Saatli B, Se&ccedil;il M. Juvenile cystic adenomyosis mimicking uterine malformation: a case report. Arch Gynecol Obstet 2008; 278:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/32\">",
"      Ho ML, Ratts V, Merritt D. Adenomyotic cyst in an adolescent girl. J Pediatr Adolesc Gynecol 2009; 22:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/33\">",
"      Tamura M, Fukaya T, Takaya R, et al. Juvenile adenomyotic cyst of the corpus uteri with dysmenorrhea. Tohoku J Exp Med 1996; 178:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/34\">",
"      Aci&eacute;n P, Bataller A, Fern&aacute;ndez F, et al. New cases of accessory and cavitated uterine masses (ACUM): a significant cause of severe dysmenorrhea and recurrent pelvic pain in young women. Hum Reprod 2012; 27:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/35\">",
"      Barbieri, RL, Propst, AM. Physical examination findings in women with endometriosis: uterosacral ligament abnormalities, lateral cervical displacement and cervical stenosis. J Gynecol Tech 1999; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/36\">",
"      Propst AM, Storti K, Barbieri RL. Lateral cervical displacement is associated with endometriosis. Fertil Steril 1998; 70:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/37\">",
"      Barbieri RL, Callery M, Perez SE. Directionality of menstrual flow: cervical os diameter as a determinant of retrograde menstruation. Fertil Steril 1992; 57:727.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2008. US Department of Health and Human Services, Atlanta, GA 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/39\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39879/abstract/40\">",
"      US Preventive Services Task Force. Screening for chlamydial infection: recommendations and rationale. Am J Prev Med 2001; 20:90.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5483 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39879=[""].join("\n");
var outline_f38_60_39879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21086905\">",
"      DEFINITIONS OF PRIMARY AND SECONDARY DYSMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52181096\">",
"      PRIMARY DYSMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21088032\">",
"      - Presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21088281\">",
"      - Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21088288\">",
"      - Laboratory and imaging findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52182240\">",
"      - Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52181508\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52181654\">",
"      - Exclusion of secondary dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H52181574\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H52181817\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H872903\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H52181831\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H873202\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52181351\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5483|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/11/3262\" title=\"figure 1\">",
"      Intrauterine pressure in dysmenorrhea with and without NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/47/10997\" title=\"figure 2\">",
"      Cervical displacement due to endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/16/22795\" title=\"table 1\">",
"      Scoring system for dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/0/18443\" title=\"table 2\">",
"      Causes of secondary dysmenorrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11402?source=related_link\">",
"      Diagnosis and treatment of endometriosis in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=related_link\">",
"      Evaluation of acute pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31864?source=related_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/47/755?source=related_link\">",
"      Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/25/31125?source=related_link\">",
"      Primary dysmenorrhea in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30681?source=related_link\">",
"      Vulvovaginal varicosities and pelvic congestion syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39880="Antiviral drug resistance among seasonal influenza viruses";
var content_f38_60_39880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiviral drug resistance among seasonal influenza viruses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/60/39880/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39880/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/60/39880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39880/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/60/39880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/60/39880/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/60/39880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H528085\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seasonal influenza is an acute respiratory illness caused by influenza A or B viruses. Influenza occurs in outbreaks and epidemics worldwide, mainly during the winter season. Although acutely debilitating, influenza is usually a self-limited infection; however, it is associated with increased morbidity and mortality in certain high risk populations.",
"   </p>",
"   <p>",
"    Two classes of antiviral drugs are available for the treatment and prevention of influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neuraminidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , which are active against both influenza A and B.",
"     </li>",
"     <li>",
"      The adamantanes,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      , which are only active against influenza A. Due to a marked increase in resistant isolates, the United States Advisory Committee on Immunization Practices (ACIP) recommends that adamantanes",
"      <strong>",
"       not",
"      </strong>",
"      be used in the United States for the treatment of influenza, except in selected circumstances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although instances of antiviral drug resistance among influenza viruses have occurred during antiviral therapy, resistant influenza strains have spread widely in the absence of such drug pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/3\">",
"     3",
"    </a>",
"    ]. Adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant seasonal H1N1 influenza A viruses since 2007, and adamantane-resistant pandemic H1N1 influenza A viruses since 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/3\">",
"     3",
"    </a>",
"    ]. Resistance to the adamantanes generally occurs more readily than resistance to the neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of antiviral resistance among influenza viruses will be presented here. The use of antiviral agents for the treatment and prevention of influenza in children and adults, as well as the pharmacology of antiviral drugs for influenza, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527111\">",
"    <span class=\"h1\">",
"     OSELTAMIVIR RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of neuraminidase inhibitor resistance affects",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    . The H274Y mutation, which results in oseltamivir resistance, emerged in 2007 and became widespread among H1N1 viruses during the 2008 to 2009 influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528621\">",
"    <span class=\"h2\">",
"     Influenza A",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14769420\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    are sialic acid analogs that competitively inhibit neuraminidase on the surface of both influenza A and B. Neuraminidase inhibitors interfere with the release of progeny influenza virus from infected cells, thereby preventing new rounds of infection. In comparison to adamantane resistance, resistance to the neuraminidase inhibitors appears to arise less readily, both in vitro and in vivo. Two mechanisms of resistance have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations that result in amino acid substitutions in the conserved active site of the neuraminidase, which usually result in drug-specific resistance. Cross-resistance may also occur with these mutations, which generally leads to reductions in infectivity and virulence in animal models. The most common neuraminidase mutation is the H274Y mutation described below. (See",
"      <a class=\"local\" href=\"#H14769427\">",
"       'H274Y mutation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H14768948\">",
"       'Epidemiology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mutations in the hemagglutinin at or near the site that binds to sialic acid residues, reducing the efficiency of viral binding which leads to diminished dependence of the viral replication cycle on neuraminidase. Such mutations confer broad cross-resistance among",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , and certain other investigational neuraminidase inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14769427\">",
"    <span class=\"h4\">",
"     H274Y mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mutation responsible for the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance that emerged among seasonal H1N1 influenza A viruses in 2007 (and rarely among 2009 pandemic H1N1 influenza A viruses) is a histidine to tyrosine substitution at amino acid 274 (H274Y) of neuraminidase; this mutation is sometimes described as &ldquo;H275Y&rdquo; using a different numbering system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The H274Y mutation reduces susceptibility of H1N1 influenza virus to oseltamivir by more than 400-fold, but does",
"    <strong>",
"     not",
"    </strong>",
"    cause resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Other mutations that confer resistance to oseltamivir",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    zanamivir have been described, although these have not caused widespread resistance to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some in vitro and animal models have suggested that neuraminidase inhibitor-resistant influenza viruses prior to 2006 may have been less fit than wild-type viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/10,14-17\">",
"     10,14-17",
"    </a>",
"    ]. However, subsequent in vitro data show that the replication capacity of viral isolates from 2007 were unimpaired compared with earlier isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/18\">",
"     18",
"    </a>",
"    ]. A nosocomial cluster of infection with an H1N1 influenza A virus harboring the H274Y mutation suggested that the mutated virus is transmissible and retains pathogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The active metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , oseltamivir carboxylate, has been detected in aquatic environments since it is poorly degraded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/20\">",
"     20",
"    </a>",
"    ]. In a study in which mallard ducks were infected with H1N1 influenza A virus and were then exposed to oseltamivir through their sole water source, the H274Y mutation dominated the influenza strains detected in fecal samples from ducks exposed to 80",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    of oseltamivir.",
"   </p>",
"   <p>",
"    The epidemiology of influenza viruses possessing the H274Y mutation is presented below. (See",
"    <a class=\"local\" href=\"#H14768948\">",
"     'Epidemiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12595465\">",
"    <span class=\"h4\">",
"     S247N mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation at residue 247 of the neuraminidase gene (S247N) confers low to moderate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance and has been detected in the Asia Pacific region since December 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14768948\">",
"     'Epidemiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14769434\">",
"    <span class=\"h4\">",
"     Other mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have shown that drug pressure may promote the development of resistance to neuraminidase inhibitors. As an example, passages of influenza viruses with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    result in glutamic acid to glycine changes at neuraminidase amino acid site 119 in influenza A and site 117 in influenza B; the net effect is decreased drug affinity and reduced enzyme stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Similar methods have generated influenza B mutants with hemagglutinin modifications that are believed to alter sialic acid binding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In vitro passages with GS 4071, the active metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , selected for an influenza A variant with two hemagglutinin mutations that resulted in a 5- to 10-fold increase in the neuraminidase IC50 for zanamivir and GS 4071 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14768948\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to 2007,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance was rare in ambulatory care settings, and emerged during treatment in 1 to 5 percent of cases in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. However, in late 2007, resistant isolates emerged in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/8,29\">",
"     8,29",
"    </a>",
"    ]. During the 2007 to 2008 influenza season, the average prevalence of resistance to oseltamivir in H1N1 isolates from Europe was 20 percent, with the highest rate (67 percent) reported in Norway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of the patients included in the initial reports of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant influenza had been taking oseltamivir, suggesting that resistant virus can be transmitted between individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. Lower rates of oseltamivir-resistant H1N1 influenza A virus were found in other regions (26 percent in Canada, 11 percent in the United States, 3 percent in Japan) between the last quarter of 2007 and June 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between October 2008 and January 2009, 185 of 190 H1N1 influenza A virus isolates (97 percent) tested from 30 states in the United States were resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/33\">",
"     33",
"    </a>",
"    ]. All isolates were susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    . High rates of oseltamivir resistance were also observed among H1N1 influenza isolates in many other regions including South Africa (100 percent), Australia (93 percent), and the Philippines (91 percent) during the 2008 to 2009 influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the onset of the 2009 H1N1 influenza A pandemic, the predominantly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -susceptible pandemic strain replaced the oseltamivir-resistant seasonal H1N1 strain worldwide. (See",
"    <a class=\"local\" href=\"#H528479\">",
"     'Pandemic H1N1 influenza A'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since December 2010, a variant of the 2009 pandemic H1N1 influenza A virus possessing a mutation at residue 247 of the neuraminidase gene (S247N) has been detected in 22 samples from the Asia Pacific region collected for the World Health Organization&rsquo;s Global Influenza Surveillance Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/21\">",
"     21",
"    </a>",
"    ]. This mutation confers low to moderate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance; the mean half maximal inhibitory concentration (IC",
"    <sub>",
"     50",
"    </sub>",
"    ) for oseltamivir was increased sixfold and for zanamivir was increased threefold. During the first three months of 2011, 9 of 28 samples (32 percent) from the Darwin region of northern Australia and 10 of 80 samples (12.5 percent) from Singapore contained the S247N mutation; the majority of isolates have been detected in two clusters in these regions. This variant has also been detected rarely since 2009 in seasonal H1N1 influenza and avian H5N1 influenza isolates in other parts of the world. When combined with the H275Y mutation, as detected in an immunocompromised patient treated with oseltamivir, the dual",
"    <span class=\"nowrap\">",
"     S247N/H274Y",
"    </span>",
"    mutant had a 7000-fold increase in IC",
"    <sub>",
"     50",
"    </sub>",
"    to oseltamivir and a fivefold increase in IC",
"    <sub>",
"     50",
"    </sub>",
"    to zanamivir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528700\">",
"    <span class=\"h4\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance mutations of influenza viruses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    appear to emerge more commonly in immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. The risk of resistance in this setting may result from prolonged viral shedding despite antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/35\">",
"     35",
"    </a>",
"    ]. In one report, for example, resistant influenza variants developed during therapy in three immunosuppressed patients with prolonged viral shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      prophylaxis when her mother was diagnosed with influenza. The patient was subsequently started on full treatment doses of oseltamivir when she developed respiratory symptoms. Despite this, the patient died of influenza B infection. A subpopulation of resistant virus with both neuraminidase and hemagglutinin mutations was recovered, which conferred a markedly reduced susceptibility to oseltamivir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Two other patients developed resistant influenza A virus with mutations in both M2 and hemagglutinin. Both viruses were resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , but susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar pattern of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance among immunocompromised patients, particularly during oseltamivir therapy, was observed during the 2009 H1N1 influenza A pandemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Drug resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528479\">",
"    <span class=\"h4\">",
"     Pandemic H1N1 influenza A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seasonal and pandemic strains of H1N1 influenza A differ notably in their resistance patterns to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    . The high rate of oseltamivir resistance among seasonal H1N1 influenza A strains during the 2008 to 2009 influenza season prior to the emergence of the pandemic contrasts with the low rate among 2009 pandemic H1N1 influenza A strains. With the onset of the 2009 H1N1 influenza A pandemic, the predominantly oseltamivir-susceptible pandemic strain replaced the oseltamivir-resistant seasonal H1N1 strain worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance that has been observed sporadically among 2009 pandemic H1N1 influenza A strains is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Drug resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528607\">",
"    <span class=\"h4\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 64 immunocompetent children with seasonal influenza treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    suggested that resistance arose more readily among H1N1 influenza A isolates (3 of 11 children) than among H3N2 influenza A (1 of 34 children) or influenza B isolates (0 of 19 children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/40\">",
"     40",
"    </a>",
"    ]. There were no significant differences in the reduction of viral shedding or time to clearance of virus between viral subtypes. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link&amp;anchor=H10#H10\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528523\">",
"    <span class=\"h3\">",
"     Severity of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 2007 to 2008 influenza season, the severity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant influenza was similar to oseltamivir-susceptible H1N1 influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, data comparing the clinical manifestations of infections with resistant and susceptible strains of the same influenza virus are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528441\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    is the preferred treatment for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant H1N1 influenza A infection. In a study of the effectiveness of oseltamivir and zanamivir for the treatment of these infections during the 2008 to 2009 season, the duration of fever after the first dose was significantly longer among patients treated with oseltamivir compared with those treated with zanamivir (49 versus 28 hours), confirming the correlation between in vitro susceptibility and clinical effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for treatment of influenza viruses with suspected or proven resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Oseltamivir resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14768997\">",
"    <span class=\"h2\">",
"     Influenza B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance has occurred in influenza A viruses, oseltamivir resistance has been observed rarely among influenza B viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/35,44-46\">",
"     35,44-46",
"    </a>",
"    ]. Neuraminidase mutations that have caused resistance to oseltamivir include D198N, G402S, and others. No cases of neuraminidase resistance among influenza B viruses have been reported during the 2010 to 2011 influenza season in the United States to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/47\">",
"     47",
"    </a>",
"    ]. Updated information about resistance patterns among circulating influenza viruses can be found at",
"    <span class=\"nowrap\">",
"     file://www.cdc.gov/flu/weekly/.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42921461\">",
"    <span class=\"h1\">",
"     ZANAMIVIR RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very little",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance has been observed to date, and the majority of cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance have not resulted in cross-resistance to zanamivir. As an example, the H274Y mutation, which is the most common cause of oseltamivir resistance among H1N1 influenza A viruses, does not cause resistance to zanamivir in vitro. (See",
"    <a class=\"local\" href=\"#H14769427\">",
"     'H274Y mutation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As noted above, since December 2010, a variant of the 2009 pandemic H1N1 influenza A virus possessing a S247N neuraminidase mutation, which confers some",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance, has been detected primarily in the Asia Pacific region. (See",
"    <a class=\"local\" href=\"#H12595465\">",
"     'S247N mutation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Few studies have directly compared the prevalence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance, given the rarity of zanamivir resistance and the less frequent use of zanamivir. During the 2005 to 2006, 2006 to 2007, 2007 to 2008, and 2008 to 2009 influenza seasons, the prevalence of drug-resistant influenza viruses and virus shedding were evaluated in 144 influenza-infected children in Japan who were treated with either oseltamivir or zanamivir (72 in each group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/48\">",
"     48",
"    </a>",
"    ]. On day one of treatment, no mutations that are known to confer neuraminidase (NA) inhibitor resistance were detected in either group. However, six children in the oseltamivir group were found to have an isolate possessing a NA resistance mutation three to seven days after beginning treatment, compared with no patients in the zanamivir group. Although there were no differences in the virus isolation rate from specimens collected on days three or four of treatment in the oseltamivir and zanamivir groups, the virus isolation rates from the specimens collected on days five to seven were significantly higher in the oseltamivir group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527125\">",
"    <span class=\"h1\">",
"     ADAMANTANE RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adamantanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    , target the M2 protein of influenza A. This protein forms an ion channel in the viral membrane that is essential for efficient viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/3\">",
"     3",
"    </a>",
"    ]. Resistance to the adamantanes can occur spontaneously or emerge as rapidly as two to three days following initiation of adamantane treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/49\">",
"     49",
"    </a>",
"    ]. Resistant viruses are genetically stable, virulent, and transmissible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The rate of spontaneous mutations resulting in drug resistance in tissue culture is quite high, ranging from 1:1000 to 1:10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14769737\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single point mutations in the codons for amino acids at positions 26, 27, 30, 31, or 34 of the M2 protein affect the transmembrane portion of this protein, the M2 ion channel, and confer cross-resistance to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/5,49,52\">",
"     5,49,52",
"    </a>",
"    ]. The mutation at position 31 is most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14769189\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread dissemination of adamantane-resistant influenza was first noted in 2003 to 2004, primarily in Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/52\">",
"     52",
"    </a>",
"    ]. Substantial rates of adamantane resistance are now present worldwide.",
"   </p>",
"   <p>",
"    In a study of more than 7000 influenza A field isolates obtained worldwide from 1994 to 2005, a significant increase in drug resistance to adamantanes was found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/52\">",
"     52",
"    </a>",
"    ]. The rates of resistance increased from 0.4 percent in 1994 to 1995 to 12.3 percent in 2003 to 2004. Sixty-one percent of resistant isolates were from Asia, where adamantanes can often be purchased over the counter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/53\">",
"     53",
"    </a>",
"    ]. Another potential contributor to increased resistance in Asia may have been related to alleged administration of adamantanes to poultry and other livestock in China and Southeast Asia to combat H9 influenza viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], and to the possible overuse of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    after the emergence of severe acute respiratory syndrome (SARS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of resistance vary with the strain of virus, but have generally increased over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/56\">",
"     56",
"    </a>",
"    ]. As an example, in a multicenter study in Japan during the 2005 to 2006 influenza season,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    resistance developed in 231 of 354 H3N2 influenza A viral isolates (65 percent) compared with none of the 61 H1N1 influenza A isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/57\">",
"     57",
"    </a>",
"    ]. In a follow-up study during the 2006 to 2007 season, there were significant increases in the incidence of both adamantane-resistant H1N1 influenza A viruses (64 versus 0 percent in 2005 to 2006) and adamantane-resistant H3N2 influenza A viruses (90 versus 65 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/58\">",
"     58",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Similar trends have been reported in the United States. The incidence of resistance was less than 2 percent until the 2004 to 2005 influenza season, when 15 percent of isolates demonstrated resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/52,55\">",
"     52,55",
"    </a>",
"    ]. During the 2005 to 2006 season, 92 percent of H3N2 influenza A viruses isolated from patients in 26 states contained an amino acid substitution at position 31 of the M2 protein, which confers resistance to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. During the 2009 to 2010 influenza season in the United States,",
"    <strong>",
"     all",
"    </strong>",
"    H3N2 influenza A and 2009 H1N1 isolates tested were resistant to the adamantanes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527132\">",
"    <span class=\"h1\">",
"     DUAL RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual resistance to adamantanes and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    has been described rarely. Among 1457 seasonal H1N1 influenza A isolates collected worldwide between 2008 and 2010, 28 viruses (1.9 percent) with dual resistance were detected from five countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/62\">",
"     62",
"    </a>",
"    ]. Twenty-one of the dually resistant viruses were collected from China, four from the United States, and one each from Canada, Kenya, and Vietnam. The resistant viruses belonged to four genetic backgrounds and resulted from several mechanisms, including exchange of M and neuraminidase genes between clade 2B and clade 2C variants, emergence of mutations conferring adamantane resistance in oseltamivir-resistant viruses during antiviral therapy, transmission from others, and possibly spontaneously (",
"    <a class=\"graphic graphic_figure graphicRef51461 \" href=\"mobipreview.htm?6/62/7136\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/60/39880/abstract/3,62\">",
"     3,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27561569\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY AND RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Updated information about influenza activity and antiviral resistance can be found on the web sites of the United States Centers for Disease Control and Prevention (",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/index.htm\">",
"     file://www.cdc.gov/flu/weekly/index.htm",
"    </a>",
"    ) and the World Health Organization",
"    <span class=\"nowrap\">",
"     (file://www.who.int/influenza/surveillance_monitoring/updates/en/).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528370\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiviral",
"      drug resistance has spread widely throughout the world, particularly against the adamantanes,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      . Adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      -resistant seasonal H1N1 influenza A viruses since 2007, and adamantane-resistant pandemic H1N1 influenza A viruses since 2009. Resistance to the adamantanes generally occurs more readily than resistance to the neuraminidase inhibitors. (See",
"      <a class=\"local\" href=\"#H528085\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to 2007, rates of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      resistance among influenza A viruses were low. However, in late 2007, increased rates of oseltamivir resistance occurred in Europe and, during the 2008 to 2009 influenza season, 97 percent of influenza A isolates tested in the United States were resistant to oseltamivir. High rates of oseltamivir resistance were also observed among H1N1 influenza isolates in many other regions. (See",
"      <a class=\"local\" href=\"#H14768948\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A notable difference between seasonal and pandemic strains of H1N1 influenza A is the resistance pattern to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      . The high rate of oseltamivir resistance among seasonal H1N1 influenza A strains during the 2008 to 2009 influenza season prior to the emergence of the pandemic contrasts with the low rate among 2009 pandemic H1N1 influenza A strains. With the onset of 2009 H1N1 influenza A pandemic, the predominantly oseltamivir-susceptible pandemic strain replaced the oseltamivir-resistant seasonal H1N1 strain worldwide. (See",
"      <a class=\"local\" href=\"#H528479\">",
"       'Pandemic H1N1 influenza A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The H1N1 mutation responsible for the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      resistance that emerged among seasonal H1N1 influenza A viruses in 2007 (and rarely among 2009 pandemic H1N1 influenza A viruses) is a histidine to tyrosine substitution at amino acid 274 (H274Y) of neuraminidase. (See",
"      <a class=\"local\" href=\"#H14769427\">",
"       'H274Y mutation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Very little",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      resistance has been observed to date, and the majority of cases of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      resistance have not resulted in cross-resistance to zanamivir. (See",
"      <a class=\"local\" href=\"#H42921461\">",
"       'Zanamivir resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Widespread dissemination of adamantane-resistant influenza was first noted in 2003 to 2004, primarily in Asia. Substantial rates of adamantane resistance are now present worldwide. All H3N2 influenza A and pandemic 2009 H1N1 isolates tested during the 2009 to 2010 influenza season in the US were resistant to the adamantanes. (See",
"      <a class=\"local\" href=\"#H14769189\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistance to the adamantanes can occur spontaneously or emerge as rapidly as two to three days following initiation of adamantane treatment. Resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      is mediated by single nucleotide changes involving the M2 ion channel, which confers cross-resistance to both of the adamantanes. (See",
"      <a class=\"local\" href=\"#H527125\">",
"       'Adamantane resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Updated information about influenza activity and antiviral resistance can be found on the web sites of the United States Centers for Disease Control and Prevention (",
"      <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/index.htm\">",
"       file://www.cdc.gov/flu/weekly/index.htm",
"      </a>",
"      ) and the World Health Organization",
"      <span class=\"nowrap\">",
"       (file://www.who.int/influenza/surveillance_monitoring/updates/en/).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H27561569\">",
"       'Influenza activity and resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations regarding the use of antivirals for seasonal influenza are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"       \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"       \"Treatment of seasonal influenza in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"       \"Prevention of seasonal influenza in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/1\">",
"      Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med 2008; 359:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/2\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/3\">",
"      Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/4\">",
"      Dolin R. Resistance to neuraminidase inhibitors. Clin Infect Dis 2011; 52:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/5\">",
"      Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/6\">",
"      Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/7\">",
"      Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir file://www.who.int/influenza/patient_care/antivirals/oseltamivir_summary/en/ (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/9\">",
"      Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/10\">",
"      Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. WHO/ECDC frequently asked questions for Oseltamivir Resistance file://www.who.int/influenza/patient_care/antivirals/oseltamivir_faqs/en/ (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/12\">",
"      Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/13\">",
"      Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/14\">",
"      Moscona A, McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA 2007; 297:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/15\">",
"      Z&uuml;rcher T, Yates PJ, Daly J, et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 2006; 58:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/16\">",
"      Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/17\">",
"      Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/18\">",
"      Baz M, Abed Y, Simon P, et al. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010; 201:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/19\">",
"      Gooskens J, Jonges M, Claas EC, et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009; 301:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/20\">",
"      J&auml;rhult JD, Muradrasoli S, Wahlgren J, et al. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One 2011; 6:e24742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/21\">",
"      Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011; 16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/22\">",
"      McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996; 225:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/23\">",
"      Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/24\">",
"      Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 1997; 176 Suppl 1:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/25\">",
"      Barnett JM, Cadman A, Burrell FM, et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/26\">",
"      Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42:3234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/27\">",
"      Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006; 194 Suppl 2:S119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/28\">",
"      Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/29\">",
"      Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/30\">",
"      Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/31\">",
"      Hauge SH, Dudman S, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15:155.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir - Last quarter 2007 to 06 March 2008 file://www.who.int/influenza/patient_care/antivirals/oseltamivir_summary/en/index.html (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Flu View: A weekly influenza surveillance report prepared by the influenza division. 2009-2009 influenza season week ending January 31, 2009 file://www.cdc.gov/flu/weekly/ (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. Influeza A (H1N1) virus resistance to oseltamivir. 2008 Southern hemisphere influenza season file://www.bepast.org/disease_information/Pandemic%20Influenza/Pandemic%20Influenza%20Information/2008_08_20H1N1_WHO_oseltamivir_resistance.pdf (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/35\">",
"      Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/36\">",
"      Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/37\">",
"      Abed Y, Baz M, Boivin G. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J Infect Dis 2009; 199:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/38\">",
"      Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. J Infect Dis 2010; 201:1397.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. 2009-2010 influenza season week 20 ending May 22, 2010 file://www.cdc.gov/flu/weekly/ (Accessed on June 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/40\">",
"      Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 48:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/41\">",
"      Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/42\">",
"      Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009; 301:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/43\">",
"      Kawai N, Ikematsu H, Hirotsu N, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009; 49:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/44\">",
"      Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/45\">",
"      Carr S, Ilyushina NA, Franks J, et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 2011; 30:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/46\">",
"      Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. FluView, 2010-2011 Influenza Season Week 01 ending January 8, 2011 file://www.cdc.gov/flu/weekly/ (Accessed on January 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/48\">",
"      Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011; 52:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/49\">",
"      Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/50\">",
"      Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/51\">",
"      Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/52\">",
"      Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/53\">",
"      Weinstock DM, Zuccotti G. Adamantane resistance in influenza A. JAMA 2006; 295:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/54\">",
"      Cyranoski D. China's chicken farmers under fire for antiviral abuse. Nature 2005; 435:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/55\">",
"      Hayden FG. Antiviral resistance in influenza viruses--implications for management and pandemic response. N Engl J Med 2006; 354:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/56\">",
"      Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/57\">",
"      Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005-2006. N Engl J Med 2007; 356:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/58\">",
"      Saito R, Suzuki Y, Li D, et al. Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006-2007 influenza season in Japan. J Infect Dis 2008; 197:630.",
"     </a>",
"    </li>",
"    <li>",
"     CDC Health Alert. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005&ndash;06 influenza season www.cdc.gov/flu/han011406.htm (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/60\">",
"      Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/60/39880/abstract/62\">",
"      Sheu TG, Fry AM, Garten RJ, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 2011; 203:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15873 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39880=[""].join("\n");
var outline_f38_60_39880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H528370\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H528085\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H527111\">",
"      OSELTAMIVIR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H528621\">",
"      Influenza A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14769420\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14769427\">",
"      H274Y mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12595465\">",
"      S247N mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14769434\">",
"      Other mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14768948\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H528700\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H528479\">",
"      Pandemic H1N1 influenza A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H528607\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H528523\">",
"      - Severity of illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H528441\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14768997\">",
"      Influenza B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42921461\">",
"      ZANAMIVIR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H527125\">",
"      ADAMANTANE RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14769737\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14769189\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H527132\">",
"      DUAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27561569\">",
"      INFLUENZA ACTIVITY AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H528370\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15873|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/62/7136\" title=\"figure 1\">",
"      Dual resistance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39881="Methylphenidate: Drug information";
var content_f38_60_39881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylphenidate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/43/7863?source=see_link\">",
"    see \"Methylphenidate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"    see \"Methylphenidate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Concerta&reg;;",
"     </li>",
"     <li>",
"      Daytrana&reg;;",
"     </li>",
"     <li>",
"      Metadate CD&reg;;",
"     </li>",
"     <li>",
"      Metadate&reg; ER;",
"     </li>",
"     <li>",
"      Methylin&reg;;",
"     </li>",
"     <li>",
"      Quillivant&trade; XR;",
"     </li>",
"     <li>",
"      Ritalin LA&reg;;",
"     </li>",
"     <li>",
"      Ritalin-SR&reg;;",
"     </li>",
"     <li>",
"      Ritalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methylphenidate&reg;;",
"     </li>",
"     <li>",
"      Apo-Methylphenidate&reg; SR;",
"     </li>",
"     <li>",
"      Biphentin&reg;;",
"     </li>",
"     <li>",
"      Concerta&reg;;",
"     </li>",
"     <li>",
"      PHL-Methylphenidate;",
"     </li>",
"     <li>",
"      PMS-Methylphenidate;",
"     </li>",
"     <li>",
"      ratio-Methylphenidate;",
"     </li>",
"     <li>",
"      Ritalin&reg;;",
"     </li>",
"     <li>",
"      Ritalin&reg; SR;",
"     </li>",
"     <li>",
"      Sandoz-Methylphenidate SR;",
"     </li>",
"     <li>",
"      Teva-Methylphenidate ER-C",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ADHD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Oral, immediate release (IR) products (tablets, chewable tablets, and solution):",
"      </i>",
"     </b>",
"     Initial: 5 mg twice daily, before breakfast and lunch; increase by 5-10 mg daily at weekly intervals; maximum dose: 60 mg daily (in 2-3 divided doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Oral, extended release (ER), sustained release (SR) products (capsules, tablets, and oral suspension):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Concerta&reg;:",
"     </i>",
"     (Adults &lt;65 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients not currently taking methylphenidate: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     U.S. labeling: 18-36 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Canadian labeling: 18 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients currently taking immediate release (IR) methylphenidate: Initial:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing based on current regimen and clinical judgment; suggested dosing listed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 5 mg 2-3 times daily",
"     <b>",
"      or",
"     </b>",
"     (Canadian labeling; not in U.S. labeling) methylphenidate SR 20 mg daily: 18 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 10 mg 2-3 times daily",
"     <b>",
"      or",
"     </b>",
"     (Canadian labeling; not in U.S. labeling) methylphenidate SR 40 mg daily: 36 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 15 mg 2-3 times daily",
"     <b>",
"      or",
"     </b>",
"     (Canadian labeling; not in U.S. labeling) methylphenidate SR 60 mg daily: 54 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 20 mg 2-3 times daily: 72 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dose adjustment: May increase dose in increments of 18 mg at weekly intervals. A dosage strength of 27 mg is available for situations in which a dosage between 18-36 mg is desired. Maximum dose: 72 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Metadate&reg; ER, Ritalin-SR&reg;:",
"     </i>",
"     May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Metadate CD&reg;, Quillivant&trade; XR:",
"     </i>",
"     Initial: 20 mg once daily; may be adjusted in 10-20 mg increments at weekly intervals; maximum: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Ritalin LA&reg;",
"     </i>",
"     : Initial: 20 mg once daily (l0 mg once daily may be considered for some patients); may be adjusted in 10 mg increments at weekly intervals; maximum: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from immediate release or sustained release methylphenidate formulation to Ritalin LA&reg;:",
"     </i>",
"     Use equivalent total daily dose administered once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Immediate release tablets and solution",
"      </i>",
"     </b>",
"     <i>",
"      (Methylin&reg;, Ritalin&reg;):",
"     </i>",
"     Initial: 5 mg twice daily before breakfast and lunch; increase by 5-10 mg daily at weekly intervals; maximum dose: 60 mg daily (in 2-3 divided doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Extended and sustained release tablets",
"      </i>",
"     </b>",
"     <i>",
"      (Metadate ER&reg;, Ritalin-SR&reg;):",
"     </i>",
"     May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Depression (unlabeled use):",
"     </b>",
"     Oral:  Initial: 2.5 mg every morning before 9 AM; dosage may be increased by 2.5-5 mg every 2-3 days as tolerated to a maximum of 20 mg daily; may be divided (ie, 7 AM and 12 noon), but should not be given after 12 noon; do not use sustained release product",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F195313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"      see \"Methylphenidate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ADHD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Oral, immediate release (IR) products (tablets, chewable tablets, and solution):",
"      </i>",
"     </b>",
"     Children &ge;6 years and Adolescents: Initial: 5 mg twice daily, before breakfast and lunch; increase by 5-10 mg daily at weekly intervals; maximum dose: 60 mg daily (in 2-3 divided doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Oral, extended release (ER), sustained release (SR) products (capsules, tablets, and oral suspension):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents &lt;18 years:",
"     <i>",
"      Concerta&reg;:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     For adolescents &ge;18 years, refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients not currently taking methylphenidate: Initial: 18 mg once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients currently taking immediate release (IR) methylphenidate: Initial:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing based on current regimen and clinical judgment; suggested dosing listed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 5 mg 2-3 times daily",
"     <b>",
"      or",
"     </b>",
"     (Canadian labeling; not in U.S. labeling) methylphenidate SR 20 mg daily: 18 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 10 mg 2-3 times daily",
"     <b>",
"      or",
"     </b>",
"     (Canadian labeling; not in U.S. labeling) methylphenidate SR 40 mg daily: 36 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 15 mg 2-3 times daily",
"     <b>",
"      or",
"     </b>",
"     (Canadian labeling; not in U.S. labeling) methylphenidate SR 60 mg daily: 54 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     - Patients taking IR methylphenidate 20 mg 2-3 times daily: 72 mg once every morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dose adjustment: May increase dose in increments of 18 mg at weekly intervals. A dosage strength of 27 mg is available for situations in which a dosage between 18-36 mg is desired.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Maximum dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     U.S. labeling: 54 mg daily in children 6-12 years",
"     <b>",
"      or",
"     </b>",
"     2 mg/kg/day (up to 72 mg daily) in adolescents &lt;18 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Canadian labeling: 54 mg daily in children and adolescents 6-18 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Metadate&reg; ER, Ritalin-SR&reg;:",
"     </i>",
"     May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Metadate CD&reg;, Quillivant&trade; XR:",
"     </i>",
"     Initial: 20 mg once daily; may be adjusted in 10-20 mg increments at weekly intervals; maximum: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Ritalin LA&reg;",
"     </i>",
"     : Initial: 20 mg once daily (l0 mg once daily may be considered for some patients); may be adjusted in 10 mg increments at weekly intervals; maximum: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Conversion from immediate release or sustained release methylphenidate formulation to Ritalin LA&reg;:",
"     </i>",
"     Use equivalent total daily dose administered once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Transdermal:",
"      </i>",
"     </b>",
"     (Daytrana&reg;): Children &ge;6 years and Adolescents &lt;18 years: Initial: 10 mg patch once daily; remove up to 9 hours after application. Titrate based on response and tolerability; may increase to next transdermal dose no more frequently than every week.",
"     <b>",
"      Note:",
"     </b>",
"     Application should occur 2 hours prior to desired effect. Drug absorption may continue for a period of time after patch removal. The prescribing information recommends patients converting from another formulation of methylphenidate should be initiated at 10 mg regardless of their previous dose and titrated as needed due to the differences in bioavailability of the transdermal formulation. However, some clinicians have supported higher starting patch doses for patients converting from oral methylphenidate doses of &gt;20 mg daily; for example, the 15 mg (18.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     ) patch has been investigated to have the same effect as 22.5 mg daily of the immediate release preparation, 27 mg/day of the osmotic release preparation, or 20 mg daily of the encapsulated bead preparation (Arnold, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral: Children &ge;6 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15967082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); undergoes extensive metabolism to a renally eliminated metabolite with little or no pharmacologic activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Transdermal: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15967083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Transdermal: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride [bi-modal release]: 10 mg [generic for Metadate CD&reg;], 20 mg [generic for Metadate CD&reg;], 20 mg [generic for Ritalin LA&reg;], 30 mg [generic for Metadate CD&reg;], 30 mg [generic for Ritalin LA&reg;], 40 mg [generic for Metadate CD&reg;], 40 mg [generic for Ritalin LA&reg;], 50 mg [generic for Metadate CD&reg;], 60 mg [generic for Metadate CD&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 10 mg [contains sucrose; 3 mg immediate release, 7 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 20 mg [contains sucrose; 6 mg immediate release, 14 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 30 mg [contains sucrose; 9 mg immediate release, 21 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 40 mg [contains sucrose; 12 mg immediate release, 28 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 50 mg [contains sucrose; 15 mg immediate release, 35 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate CD&reg;: 60 mg [contains sucrose; 18 mg immediate release, 42 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 10 mg [5 mg immediate release, 5 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 20 mg [10 mg immediate release, 10 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 30 mg [15 mg immediate release, 15 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin LA&reg;: 40 mg [20 mg immediate release, 20 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 10 mg/9 hours (30s) [12.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 27.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 15 mg/9 hours (30s) [18.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 41.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 20 mg/9 hours (30s) [25 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 55 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daytrana&reg;: 30 mg/9 hours (30s) [37.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total methylphenidate 82.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, extended release, oral, as hydrochloride [bi-modal release]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quillivant&trade; XR: 25 mg/5 mL (60 mL, 120 mL, 150 mL, 180 mL) [contains sodium benzoate; banana flavor; 5 mg immediate release, 20 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (500 mL); 10 mg/mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin&reg;: 10 mg, 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 2.5 mg [contains phenylalanine 0.42 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 5 mg [contains phenylalanine 0.84 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methylin&reg;: 10 mg [scored; contains phenylalanine 1.68 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metadate&reg; ER: 20 mg [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride [bi-modal release]: 18 mg, 27 mg, 36 mg, 54 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 18 mg [4 mg immediate release, 14 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 27 mg [6 mg immediate release, 21 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 36 mg [8 mg immediate release, 28 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concerta&reg;: 54 mg [12 mg immediate release, 42 mg extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritalin-SR&reg;: 20 mg [dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Extended release capsule, extended/sustained release tablet, immediate release tablet, immediate release oral solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F195330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Concerta&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088575.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088575.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Daytrana&reg;:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021514s009s010MedGuide.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021514s009s010MedGuide.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metadate CD&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088635.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088635.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methylin&reg; chewable tablet:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088639.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088639.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methylin&reg;  immediate release oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088640.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088640.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Quillivant&trade; XR extended release oral suspension:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322209.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322209.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089090.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089090.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin LA&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089092.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089092.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ritalin-SR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089095.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089826.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release (IR) tablet (Ritalin&reg;), IR solution (Methylin&reg;), chewable tablet (Methylin&reg;): Administer each dose 30-45 minutes before a meal. Ensure last daily dose is administered before 6 pm if difficulty sleeping occurs. Administer chewable tablet with at least 8 ounces of water or other fluid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule (Metadate CD&reg;, Ritalin LA&reg;): Administer in the morning.  May be taken with or without food. Alternatively, capsules may be opened and the contents sprinkled onto a small amount (equal to 1 tablespoon) of cold applesauce. Swallow applesauce without chewing. Do not crush or chew capsule contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release suspension (Quillivant&trade; XR): Administer in the morning with or without food.  Shake bottle &ge;10 seconds prior to administration. Use the oral dosing dispenser provided; wash after each use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Metadate&reg; ER: May be taken with or without food. Swallow whole with water or other fluid; do not crush or chew tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Concerta&reg;: Administer in the morning. May be taken with or without food, but must be taken with water or other fluid. Do not crush, chew, or divide tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release tablet (Ritalin-SR&reg;): Administer 30-45 minutes before a meal. Swallow whole; do not crush or chew tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Transdermal (Daytrana&reg;): Apply to clean, dry, non-oily, intact skin to the hip area, avoiding the waistline; do not premedicate the patch site with hydrocortisone or other solutions, creams, ointments, or emollients. Apply at the same time each day to alternating hips. Press firmly for 30 seconds to ensure proper adherence. Avoid exposure of application site to external heat source, which may increase the amount of drug absorbed. If difficulty is experienced when separating the patch from the liner or if any medication (sticky substance) remains on the liner after separation; discard that patch and apply a new patch. Do not use a patch that has been damaged or torn; do not cut patch. If patch should dislodge, may replace with new patch (to different site) but total wear time should not exceed 9 hours; do not reapply with dressings, tape, or common adhesives. Patch may be removed early if a shorter duration of effect is desired or if late day side effects occur. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch. If patch removal is difficult, an oil-based product (eg, petroleum jelly, olive oil) may be applied to the patch edges to aid removal; never apply acetone-based products (eg, nail polish remover) to patch. Dispose of used patch by folding adhesive side onto itself, and discard in toilet or appropriate lidded container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD); symptomatic management of narcolepsy (except Concerta&reg;, Daytrana&reg;, Metadate CD&reg;, Ritalin LA&reg;, and Quillivant&trade; XR)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metadate CD&reg; may be confused with Metadate&reg; ER",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metadate&reg; ER may be confused with methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methylphenidate may be confused with methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ritalin&reg; may be confused with Rifadin&reg;, ritodrine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ritalin LA&reg; may be confused with Ritalin-SR&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      All dosage forms:",
"     </b>",
"     Frequency not always defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, cardiac arrhythmia, cerebral arteritis, cerebral hemorrhage, cerebral occlusion, cerebrovascular accidents, hyper-/hypotension, MI, murmur, palpitation, pulse increased/decreased, Raynaud&rsquo;s phenomenon, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Motion sickness (children 2%), tic (children 2%), aggression, agitation, anger, anxiety, confusional state, depression, dizziness, drowsiness, emotional lability, fatigue, fever, headache, hypervigilance, insomnia, irritability, lethargy, nervousness, neuroleptic malignant syndrome (NMS) (rare), restlessness, stroke, tension, Tourette's syndrome (rare), toxic psychosis, tremor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Excoriation (children 4%), alopecia, erythema multiforme, exfoliative dermatitis, hyperhidrosis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, growth retardation, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, bruxism, constipation, diarrhea, dyspepsia, nausea, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Erectile dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, pancytopenia, thrombocytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, hepatic coma, liver function tests abnormal, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, dyskinesia, muscle tightness, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Eye pain (children 2%), blurred vision, dry eyes, mydriasis, visual accommodation disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Necrotizing vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough increased, dyspnea, pharyngitis, pharyngolaryngeal pain, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental injury, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Alkaline phosphatase increased, bradycardia, disorientation, extrasystole, hallucinations; hypersensitivity reactions (eg, angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticaria, pruritus, rash, eruptions, exanthemas); mania, migraine, obsessive-compulsive disorder, priapism, seizure, supraventricular tachycardia, ventricular extrasystole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal system:",
"     </b>",
"     Frequency of adverse events as reported in trials of 7-week duration. Incidence of some events higher with extended use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (&le;15%; long-term use in children: 28%), insomnia (6% to 13%; long-term use in children: 30%), irritability (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (26%), nausea (10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (long-term use in children: 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Tic (7%), dizziness (adolescents 6%), emotional instability (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (3% to 10%), weight loss (6% to 9%), abdominal pain (5% to 7%), anorexia (5%; long-term use in children: 46%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (6%) nasopharyngitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Allergic contact dermatitis/sensitization, anaphylaxis, angioedema, hallucinations, seizures",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylphenidate or any component of the formulation; marked anxiety, tension, and agitation; glaucoma; use during or within 14 days following MAO inhibitor therapy; family history or diagnosis of Tourette's syndrome or tics",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metadate CD&reg; and Metadate&reg; ER: Additional contraindications: Severe hypertension, heart failure, arrhythmia, hyperthyroidism, recent MI or angina; concomitant use of halogenated anesthetics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events (eg, sudden death in children and adolescents; sudden death, stroke, and MI in adults) in patients with pre-existing structural cardiac abnormalities or other serious heart problems. These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could further increase their risk of sudden death. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Some products are contraindicated in patients with heart failure, arrhythmias or recent MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Visual disturbance: Difficulty in accommodation and blurred vision have been reported with the use of stimulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential:",
"     <b>",
"      [U.S. Boxed Warning]: Potential for drug dependency exists; avoid abrupt discontinuation in patients who have received for prolonged periods.",
"     </b>",
"     Use caution in patients with history of ethanol or drug abuse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Some products are contraindicated in patients with severe hypertension, hyperthyroidism or angina.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new-onset psychosis or mania may occur with stimulant use; observe for symptoms of aggression and/or hostility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not labeled for use in children &lt;6 years of age. Use of stimulants has been associated with suppression of growth in children; monitor growth rate during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Concerta&reg;: Should not be used with pre-existing severe gastrointestinal narrowing conditions, such as esophageal motility disorders, small bowel disease, &ldquo;short&rdquo; gut syndrome, cystic fibrosis, history of peritonitis, chronic intestinal pseudo-obstruction, or Meckel&rsquo;s diverticulum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Daytrana&reg;: Transdermal system may cause allergic contact sensitization, characterized by intense local reactions (eg, edema, papules) that may spread beyond the patch site; sensitization may subsequently manifest systemically with other routes of methylphenidate administration; monitor closely. Avoid exposure of application site to any direct external heat sources (eg, hair dryers, heating pads, electric blankets); may increase the rate and extent of absorption and risk of overdose. Efficacy of therapy for &gt;7 weeks has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Metadate CD&reg;: Contains sucrose; avoid administration in fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency. Concomitant use with halogenated anesthetics is contraindicated; may cause sudden elevations in blood pressure; if surgery is planned, do not administer Metadate CD&reg; on the day of surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Metadate&reg; ER: Contains lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Concomitant use with halogenated anesthetics is contraindicated; may cause sudden elevations in blood pressure; if surgery is planned, do not administer Metadate&reg; ER on the day of surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Methylphenidate may diminish the antihypertensive effect of Antihypertensives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Minoxidil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Methylphenidate may enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: Methylphenidate may enhance the adverse/toxic effect of CloNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Methylphenidate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: Methylphenidate may enhance the hypertensive effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Methylphenidate may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Methylphenidate may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Methylphenidate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Methylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Methylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Methylphenidate may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F195292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may increase oral absorption of immediate release tablet/solution and chewable tablet. Management: Administer 30-45 minutes before meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Ephedra may cause hypertension or arrhythmias and yohimbe has CNS stimulatory activity. Management: Avoid ephedra and yohimbe.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown teratogenic effects to the fetus. There are no adequate and well-controlled studies in pregnant women. Do not use in women of childbearing age unless the potential benefit outweighs the possible risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3277308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methylphenidate excretion into breast milk has been noted in case reports. In both cases, the authors calculated the relative infant dose to be &le;0.2% of the weight adjusted maternal dose. Adverse events were not noted in either infant, however, both were older (6 months of age and 11 months of age) and exposure was limited.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F195282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer immediate release (IR) tablet (Ritalin&reg;), IR solution (Methylin&reg;), chewable tablet (Methylin&reg;), and sustained released tablet (Ritalin-SR&reg;) 30-45 minutes before meals. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Methylphenidate HCl ER (LA) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $493.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $504.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $518.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Ritalin LA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $630.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $630.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $644.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $662.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Metadate CD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $684.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $684.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $684.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $938.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $1152.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $1152.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Methylphenidate HCl ER (CD) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $560.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $560.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $560.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $711.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $944.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $944.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Methylin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $351.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $501.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $715.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch",
"     </b>",
"     (Daytrana Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/9 hrs (30): $233.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/9 hrs (30): $233.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/9 hrs (30): $233.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/9 hrs (30): $233.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methylin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (500 mL): $502.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (500 mL): $715.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methylphenidate HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (500 mL): $451.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (500 mL): $643.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Quillivant XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (120 mL): $210.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Concerta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18 mg (100): $791.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     27 mg (100): $811.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     36 mg (100): $836.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     54 mg (100): $910.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Metadate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $197.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Methylphenidate HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $83.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18 mg (100): $622.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $111.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     27 mg (100): $637.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     36 mg (100): $657.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     54 mg (100): $715.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Ritalin SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $266.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methylphenidate HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $33.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $47.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $68.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ritalin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $78.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $112.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $161.59",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC, differential, and platelet counts with prolonged use; blood pressure, heart rate; signs and symptoms of depression, aggression, or hostility; growth rate in children; signs of central nervous system stimulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Transdermal: Signs of worsening erythema, blistering or edema which does not improve within 48 hours of patch removal, or spreads beyond patch site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk.  Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adaphen (ZA);",
"     </li>",
"     <li>",
"      Adaphen XL (ZA);",
"     </li>",
"     <li>",
"      Aradix (CN);",
"     </li>",
"     <li>",
"      Concerta (AT, AU, BB, BE, BG, BM, BS, BZ, CH, CL, CO, CR, DO, EC, ES, FI, GR, GT, GY, HK, ID, IL, JM, MX, MY, NI, NL, NO, NZ, PA, PH, PL, PR, PT, SE, SG, SR, SV, TH, TR, TT, TW);",
"     </li>",
"     <li>",
"      Concerta LP (FR);",
"     </li>",
"     <li>",
"      Concerta Oros (KP);",
"     </li>",
"     <li>",
"      Concerta XL (GB);",
"     </li>",
"     <li>",
"      Equasym XL (GB, IE);",
"     </li>",
"     <li>",
"      Metadate CD SR (KP);",
"     </li>",
"     <li>",
"      Penid (KP);",
"     </li>",
"     <li>",
"      Prohiper (ID);",
"     </li>",
"     <li>",
"      Rilatine (LU);",
"     </li>",
"     <li>",
"      Ritalin (AE, AT, AU, BF, BH, BJ, CH, CI, CO, CY, CZ, DE, DK, EG, ET, GB, GH, GM, GN, HK, HN, ID, IE, IL, IQ, IR, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PE, PK, QA, SA, SC, SD, SE, SG, SL, SN, SY, TN, TW, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ritalin LA (AU, CO, HK, ID, IL, MY, PE, PT, TR);",
"     </li>",
"     <li>",
"      Ritalin-SR (CH, HK, ID, MY, NZ, SG);",
"     </li>",
"     <li>",
"      Ritalina (AR, BR, PY, UY);",
"     </li>",
"     <li>",
"      Ritaline (BE, FR, GR);",
"     </li>",
"     <li>",
"      Ritaline LP (FR);",
"     </li>",
"     <li>",
"      Rubifen (CN, ES, MY, NZ, PT, SG, TH);",
"     </li>",
"     <li>",
"      Tradea (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild CNS stimulant; blocks the reuptake of norepinephrine and dopamine into presynaptic neurons; appears to stimulate the cerebral cortex and subcortical structures similar to amphetamines",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Cerebral stimulation: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: Metadate CD&reg;, Ritalin LA&reg;: Biphasic; initial peak similar to immediate release product, followed by second rising portion (corresponding to extended release portion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: Concerta&reg;: Initial: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release tablet: Ritalin-SR&reg;: 4-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: ~2 hours; may be expedited by the application of external heat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release tablet: 3-6 hours; Sustained release tablet: Ritalin-SR&reg;: 8 hours; Extended release tablet: Metadate&reg; ER: 8 hours, Concerta&reg;: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chewable tablet: Methylin&reg;: A high-fat meal delayed peak time (~1 hour) and increased AUC (~20%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Metadate CD&reg;: A high-fat meal delayed the early peak (~1 hour), and increased C",
"     <sub>",
"      max",
"     </sub>",
"     (~30%) and AUC (~17%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Ritalin LA&reg;: A high-fat meal delayed absorption and peak times, but not the amount absorbed nor initial peak concentration (second peak lowered by ~25%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release suspension: Quillivant&trade; XR: A high-fat meal led to an earlier peak (~1 hour), and increased C",
"     <sub>",
"      max",
"     </sub>",
"     (~28%) and AUC (~19%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release tablet: Metadate&reg; ER:  Food resulted in greater C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC compared to fasting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release solution: Methylin&reg;: A high-fat meal delayed peak time (~1 hour), and increased C",
"     <sub>",
"      max",
"     </sub>",
"     (~13%) and AUC (~25%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Absorption increased when applied to inflamed skin or exposed to heat. Absorption is continuous for 9 hours after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"     <i>",
"      d",
"     </i>",
"     -methylphenidate: 2.65 &plusmn; 1.11 L/kg,",
"     <i>",
"      l",
"     </i>",
"     -methylphenidate: 1.80 &plusmn; 0.91 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive metabolism, predominately via de-esterification by carboxylesterase CES1A1 to alpha-phenyl-piperidine acetic acid (PPAA; ritalinic acid) which has little to no pharmacologic activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Extended release suspension: Quillivant&trade; XR: 95% (relative to immediate release oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"     <i>",
"      d",
"     </i>",
"     -methylphenidate: 3-6 hours;",
"     <i>",
"      l",
"     </i>",
"     -methylphenidate: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Concerta&reg;: C",
"     <sub>",
"      max",
"     </sub>",
"     : 6-8 hours; Daytrana&reg;: 7.5-10.5 hours; Quillivant&trade; XR: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% as metabolites and unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnold LE, Lindsay RL, L&oacute;pez FA, et al, \"Treating Attention-Deficit/Hyperactivity Disorder With a Stimulant Transdermal Patch: The Clinical Art,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(5):1100-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/17974748/pubmed\" id=\"17974748\" target=\"_blank\">",
"        17974748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bond WS, &ldquo;Recognition and Treatment of Attention Deficit Disorder,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1987, 6(8):617-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/2891464/pubmed\" id=\"2891464\" target=\"_blank\">",
"        2891464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emptage RE and Semla TP, &ldquo;Depression in the Medically Ill Elderly: A Focus on Methylphenidate,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/8835049/pubmed\" id=\"8835049\" target=\"_blank\">",
"        8835049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenhill LL, &ldquo;Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1992, 15(1):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/1347936/pubmed\" id=\"1347936\" target=\"_blank\">",
"        1347936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurian B and Rosowsky E, &ldquo;Low-Dose Methylphenidate in the Very Old,&rdquo;",
"      <i>",
"       J Geriatr Psychiatry Neurol",
"      </i>",
"      , 1990, 3(3):152-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/2282131/pubmed\" id=\"2282131\" target=\"_blank\">",
"        2282131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011,",
"      <i>",
"       JAMA",
"      </i>",
"      , 306(24):2673-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/22161946/pubmed\" id=\"22161946\" target=\"_blank\">",
"        22161946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hackett LP, Kristensen JH, Hale TW, et al, &ldquo;Methylphenidate and Breast-Feeding,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(10):1890-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/16940409/pubmed\" id=\"16940409\" target=\"_blank\">",
"        16940409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katon W and Raskind M, &ldquo;Treatment of Depression in the Medically Ill Elderly With Methylphenidate,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1980, 137(8):963-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/7416300/pubmed\" id=\"7416300\" target=\"_blank\">",
"        7416300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly DP and Aylward GP, &ldquo;Attention Deficits in School-Aged Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(3):487-512.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/1574355/pubmed\" id=\"1574355\" target=\"_blank\">",
"        1574355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lazarus LW, Moberg PJ, Langsley PR, et al, &ldquo;Methylphenidate and Nortriptyline in the Treatment of Poststroke Depression: A Retrospective Comparison,&rdquo;",
"      <i>",
"       Arch Phys Med Rehabil",
"      </i>",
"      , 1994, 75(4):403-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/8172499/pubmed\" id=\"8172499\" target=\"_blank\">",
"        8172499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manzi S, Law T, Shannon MW, et al, &ldquo;Methylphenidate Produces a False-Positive Urine Amphetamine Screen,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2002, 18(5):401.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/12395015/pubmed\" id=\"12395015\" target=\"_blank\">",
"        12395015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Modi NB, Lindemulder B, and Gupta SK, &ldquo; Single- and Multiple-Dose Pharmacokinetics of an Oral Once-a-day Osmotic Controlled-release OROS (Methylphenidate HCl) Formulation,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2000, 40(4):379-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/10761165/pubmed\" id=\"10761165\" target=\"_blank\">",
"        10761165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, &ldquo;ADHD and Cardiovascular Risk,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(14):1445-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/16549404/pubmed\" id=\"16549404\" target=\"_blank\">",
"        16549404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaywitz SE and Shaywitz BA, &ldquo;Diagnosis and Management of Attention Deficit Disorder: A Pediatric Perspective,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1984, 31(2):429-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/6728525/pubmed\" id=\"6728525\" target=\"_blank\">",
"        6728525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigset O, Brede WR, and Zahlsen K, &ldquo;Excretion of Methylphenidate in Breast Milk,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(2):348.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/17267805/pubmed\" id=\"17267805\" target=\"_blank\">",
"        17267805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace AE, Kofoed LL and West AN, &ldquo;Double-Blind, Placebo-Controlled Trial of Methylphenidate in Older, Depressed, Medically Ill Patients,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(6):929-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/7755127/pubmed\" id=\"7755127\" target=\"_blank\">",
"        7755127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss MD and Weiss JR, &ldquo;A Guide to the Treatment of Adults With ADHD,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2004, 65(Suppl 3):27-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/15046533/pubmed\" id=\"15046533\" target=\"_blank\">",
"        15046533",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE and Biederman J, &ldquo;The Stimulants,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1992, 15(1):191-222.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/60/39881/abstract-text/1347939/pubmed\" id=\"1347939\" target=\"_blank\">",
"        1347939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9638 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39881=[""].join("\n");
var outline_f38_60_39881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709144\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195295\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195296\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195328\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195300\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195313\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195301\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15967082\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15967083\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195272\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195256\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195330\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874704\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195275\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195274\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195326\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195278\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195260\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195323\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195265\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195292\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195267\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195281\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195304\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3277308\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195282\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989423\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195269\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195283\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195259\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195277\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9638|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/43/7863?source=related_link\">",
"      Methylphenidate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=related_link\">",
"      Methylphenidate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_60_39882="Light micrograph showing collapsing FGS";
var content_f38_60_39882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81601%7ENEPH%2F59839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81601%7ENEPH%2F59839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing collapsing FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing collapsing glomerulosclerosis with few open loops in the sclerotic areas (long arrows); these findings are characteristic of HIV nephropathy but can also be seen in idiopathic disease. The degree of collapse can be appreciated by the openness of Bowman's space. Vacuolization and crowding of the glomerular epithelial cells (short arrows) is also frequently seen and reflects the primary epithelial cell injury in this disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph showing tubuloreticular structures in HIV nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in HIV-induced focal collapsing glomerulosclerosis shows numerous intraendothelial (End) tubuloreticular structures (arrow). These structures are not seen in the idiopathic form of the disease. The epithelial cell (Ep) has no discrete foot processes, a reflection of primary epithelial cell injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39882=[""].join("\n");
var outline_f38_60_39882=null;
var title_f38_60_39883="Migrainous vertigo criteria";
var content_f38_60_39883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed criteria for migrainous vertigo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Proposed criteria for definite migrainous vertigo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A. Recurrent episodic vestibular symptoms of at least moderate severity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B. Current or previous history of migraine according to the criteria of the IHS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       C. One of the following migrainous symptoms during at least two vertiginous attacks:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Migrainous headache",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Photophobia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Phonophobia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       4. Visual or other auras",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D. Other causes ruled out by appropriate investigations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Proposed criteria for probable migrainous vertigo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A. Recurrent episodic vestibular symptoms of at least moderate severity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       B. One of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Current or previous history of migraine according to the criteria of the IHS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Migrainous symptoms during &ge;2 vertiginous attacks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Migraine precipitants before vertigo in more than 50 percent of attacks: food triggers, sleep irregularities, hormonal changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       4. Response to migraine medications in more than 50 percent of attacks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C. Other causes ruled out by appropriate investigations",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia 2004; 24:83.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39883=[""].join("\n");
var outline_f38_60_39883=null;
var title_f38_60_39884="Immunosuppressive agents";
var content_f38_60_39884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunosuppressive agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td>",
"        <p>",
"         Suppresses leukocyte, macrophage, and cytotoxic T-cell activity",
"        </p>",
"        <p>",
"         Decreases cytokines, prostaglandins, and leukotrienes",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hypertension",
"        </p>",
"        <p>",
"         Dyslipidemia",
"        </p>",
"        <p>",
"         Glucose intolerance",
"        </p>",
"        <p>",
"         Bone abnormalities",
"        </p>",
"        <p>",
"         Peptic ulcers",
"        </p>",
"        <p>",
"         Psychiatric disorders",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        <p>",
"         Inactivates calcineurin",
"        </p>",
"        <p>",
"         Decreases IL-2 production",
"        </p>",
"        <p>",
"         Inhibits T-cell activation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hypertension",
"        </p>",
"        <p>",
"         Renal insufficiency",
"        </p>",
"        <p>",
"         Neuropathy",
"        </p>",
"        <p>",
"         Hyperlipidemia",
"        </p>",
"        <p>",
"         Gingival hyperplasia",
"        </p>",
"        <p>",
"         Hirsutism",
"        </p>",
"        <p>",
"         Insulin resistance",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tacrolimus",
"       </td>",
"       <td>",
"        <p>",
"         Inactivates calcineurin",
"        </p>",
"        <p>",
"         Decreases IL-2 production",
"        </p>",
"        <p>",
"         Inhibits T-cell activation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hypertension",
"        </p>",
"        <p>",
"         Renal insufficiency",
"        </p>",
"        <p>",
"         Insulin resistance",
"        </p>",
"        <p>",
"         Neuropathy",
"        </p>",
"        <p>",
"         Hyperlipidemia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Azathioprine",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits adenosine and guanine production",
"        </p>",
"        <p>",
"         Inhibits DNA and RNA synthesis in rapidly proliferating T cells",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Leukopenia",
"        </p>",
"        <p>",
"         Anemia",
"        </p>",
"        <p>",
"         Thrombocytopenia",
"        </p>",
"        <p>",
"         Pancreatitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mycophenolate mofetil or mycophenolic acid",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits production of inosine monophosphate dehydrogenase (IMPDH)",
"        </p>",
"        <p>",
"         Prevents T and B cell proliferation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Leukopenia",
"        </p>",
"        <p>",
"         Anemia",
"        </p>",
"        <p>",
"         Thrombocytopenia",
"        </p>",
"        <p>",
"         GI side effects",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sirolimus",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits mTOR, (target of Rapamycin)",
"        </p>",
"        <p>",
"         Prevents T-cell replication",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Leukopenia",
"        </p>",
"        <p>",
"         Thrombocytopenia",
"        </p>",
"        <p>",
"         Hyperlipidemia",
"        </p>",
"        <p>",
"         Hepatic artery thrombosis",
"        </p>",
"        <p>",
"         Inhibited wound healing",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39884=[""].join("\n");
var outline_f38_60_39884=null;
var title_f38_60_39885="Hand-sewn ileocolic anastomosis - Lembert sutures";
var content_f38_60_39885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-sewn ileocolic anastomosis - Lembert sutures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39885=[""].join("\n");
var outline_f38_60_39885=null;
var title_f38_60_39886="IGF receptors in insulin resistance";
var content_f38_60_39886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Possible mechanisms by which insulin resistance leads to the clinical manifestations of the polycystic ovary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insulin resistance in muscle and adipose tissue leads to hyperglycemia and thus increased insulin secretion from the pancreatic beta cells. This insulin can cause changes in the skin, ovary, and cartilage via activation of insulin-like growth factor-1 (IGF-1) receptors or hybrid receptors formed by covalent linkage of subunits of the homologous receptors for insulin (IR) and IGF-1 (IGF-R).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum.&nbsp;Adv Endocrinol Metab 1995; 6:193.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39886=[""].join("\n");
var outline_f38_60_39886=null;
var title_f38_60_39887="Bronchial atresia CT II";
var content_f38_60_39887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe bronchial atresia seen on an axial CT image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT scan with lung window settings shows marked hyperexpansion of the left upper lobe a tubular branching hilar mass and absence of the proximal left upper lobe bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_60_39887=[""].join("\n");
var outline_f38_60_39887=null;
  